The mainstream Alzheimer's hypothesis is again being questioned

Alzheimer's disease, known as the "eraser in the mind," is a neurodegenerative disease with an unclear pathogenesis
and no cure.

Suspected of counterfeiting

For many years, drug development for Alzheimer's disease has been based primarily on the most recognized "hypothesis" – β amyloid deposition
.

Until 2006, the University of Minnesota graduate student Sylvain Leone published a paper as the first author of the British journal Nature, directly proving in mouse models that the subtype of β amyloid Aβ*56 is neurotoxic, which can cause dementia in mice, which is equivalent to re-injecting a "cardiotonic needle" into the amyloid hypothesis of β, when Nature commented that Aβ*56 was the "number one suspect"
of Alzheimer's disease.

This is the paper that is suspected of being a fake, and the suspect is found to be Matthew Schlager, a neuroscientist at Vanderbilt University in the
United States.

Schrage sent the findings to Science, which then launched a six-month investigation with evidence strongly supporting Schrage's suspicions
.

However, at present, it has not yet been decided
whether the paper confirms the fraud.

The controversy is hard to come by

According to Science, Schrage's findings could threaten major theories in the field of Alzheimer's disease, and statistics show that the paper has been cited more than 2300 times
.

However, some neuroscience experts interviewed by the reporter said that the questionable paper has not yet shaken the current mainstream status
of the β amyloid hypothesis.

In fact, there has always been controversy over the β amyloid hypothesis
.

Develop black holes

Alzheimer's disease drugs have always been the "black hole" of pharmaceutical research and development, with huge investment in decades but little
effect.

The American Association of Drug Research Institutes and Pharmaceutical Manufacturers reported that between 1998 and 2017, a total of 146 clinical trials of Alzheimer's disease drugs failed
.

However, experts believe that the research and development of new drugs for Alzheimer's disease in the controversy, new targets and new hopes are constantly emerging, and have entered the "era of great navigation"
.

According to a report released by the Alzheimer's Disease Drug Discovery Foundation, the existing Alzheimer's disease R&D pipeline is not only focused on β amyloid and tau proteins, but also targets a variety of innovative targets
.